Italian researcher Alba Grifoni special guest of a scientific webinar promoted and organized by ICCB next Thursday, February 25th 2021

Within the informative/training and business assistance activities, the Italian Chamber of Commerce in Bulgaria and Lot Consult, a leading associated company in the sector of health and safety at work in Bulgaria, organize a scientific webinar entitled How the immune system responds to SARS-CoV-2, the virus that causes COVID-19. The best reaction for keeping healthy and safe workplaces” Thursday February, 25th, 2021 from 18h30 (EET) via ZOOM platform.

The goal is to provide a moment of concrete information capable of improving the prevention and management of the pandemic in the places of life and work in this new phase of the pandemic emergency marked by vaccines, combined with the desire to illustrate the studies and research on the immune system conducted in the scientific field to tackle Covid-19.

To properly deal with the pandemic emergency currently, a pandemic of a globalized society where what happens in distant places arrives quickly in our living and working places, it is important not only to apply correct behaviors but also to carry out adequate prevention, which necessarily passes through a suitable immune prophylaxis, through a vaccine.

The problem is that in the “vaccination” phase of the Covid-19 emergency, the complexity of the global pandemic situation leads many to cultivate scepticism. The decision – to be vaccinated or not to be vaccinated? – is made even more complicated by the excess of data that favors the dissemination of misleading information that can hinder the effectiveness of emergency management.

The online event will see the special participation of the young Italian researcher from San Diego, Ph.D. Alba Grifoni who will make a valuable contribution by illustrating the results of her research, worthy of mention by the guru and well-known virologist Anthony Fauci.

Chamber members, representatives of trade associations, TOP managers and employers, representatives of the medical-health and scientific-academic world, corporate health & safety managers, radio and television operators and the specialized press are invited to participate.

Participation is free, upon registration to be sent no later than  February, 25th 2021 at 14h (EET) to (Giulia Pashang).

Working language | English

Viewing mode | Zoom platform

Member and Partner participation | free upon registration

Info and questions to the speaker|

Alba Grifoni, Ph.D. in Immunology, infectious disease researcher at La Jolla Institute for Immunology (LJI) based in San Diego, received the ” Embassy of Italy ” Award to Honor Young Italian researchers for research in COVID -19 from the Italian Scientists and Scholars in North America Foundation (ISSNAF). The award honors Grifoni’ssignificant advances in understanding how the immune system responds to SARS-CoV-2, the virus that causes COVID-19.

After bachelor’s and master’s degrees in Human Biology at the Tor Vergata University of Rome, Dr. Grifoni obtained the Ph.D. in Immunology in 2014 at the same University. In the following years she spent a training period in Bulgaria as a junior researcher at Proxagen Ltd.

From 2016 to 2019 she is at La Jolla Institute for Immunology in San Diego as postdoctoral fellow in the laboratory directed by another Italian, Alessandro Sette and recently promoted to the position of Instructor/Research faculty.

She is currently working on COVID-19 and in one of her most recent studies she used immune-informatic analysis to predict T cell epitopes, using IEDB. She then expanded this study to identify dissect SARS-CoV-2 specific T cell responses in unexposed and COVID-19 patients with mild symptoms at the convalescent phase. This study led to a recent publication in the prestigious Cell journal.

Her passion and deep knowledge of viral immunology led to pioneering findings in the context of COVID-19 research. Her first-author paper focused on T cells in COVID-19 patients was mentioned by Dr. Fauciduring a congress meeting in Washington and was critical in COVID-19 vaccine research.

2021-02-21T23:48:26+02:00February 16th, 2021|
This website uses cookies and third party services. Ok